Research programme: oral fator Xa inhibitors - Bristol-Myers Squibb
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in USA (PO)
- 12 Apr 2007 Preclinical trials in Thrombosis in USA (PO)